{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=13",
    "query": {
      "condition": "Immune Dysfunction",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 20596,
    "total_pages": 2060,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T00:03:55.226Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04052997",
      "title": "Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsed Hodgkin Lymphoma",
        "Refractory Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Camidanlumab Tesirine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ADC Therapeutics S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 117,
      "start_date": "2019-09-13",
      "completion_date": "2023-01-19",
      "has_results": true,
      "last_update_posted_date": "2024-03-28",
      "last_synced_at": "2026-10-18T00:03:55.226Z",
      "location_count": 24,
      "location_summary": "Scottsdale, Arizona • Duarte, California • San Francisco, California + 19 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04052997"
    },
    {
      "nct_id": "NCT00003613",
      "title": "O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Stage I Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Stage II Cutaneous T-cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "O6-benzylguanine",
          "type": "DRUG"
        },
        {
          "name": "carmustine",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "1999-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-11",
      "last_synced_at": "2026-10-18T00:03:55.226Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003613"
    },
    {
      "nct_id": "NCT05442580",
      "title": "CART-38 in Adult AML and MM Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)",
        "Multiple Myeloma (MM)"
      ],
      "interventions": [
        {
          "name": "3x10(6) CART-38 cellls",
          "type": "DRUG"
        },
        {
          "name": "7x10(5) CART-38 cells",
          "type": "DRUG"
        },
        {
          "name": "7x10(6) CART-38 cells",
          "type": "DRUG"
        },
        {
          "name": "3x10(7) CART-38 cells",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2023-05-30",
      "completion_date": "2025-02-09",
      "has_results": false,
      "last_update_posted_date": "2025-06-26",
      "last_synced_at": "2026-10-18T00:03:55.226Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05442580"
    },
    {
      "nct_id": "NCT01523496",
      "title": "Vitamin D Supplementation in HIV Youth",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Vitamin D control dose",
          "type": "DRUG"
        },
        {
          "name": "Vitamin D supplementation-",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University Hospitals Cleveland Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "8 Years to 25 Years"
      },
      "enrollment_count": 190,
      "start_date": "2011-12",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2018-03-08",
      "last_synced_at": "2026-10-18T00:03:55.226Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Cleveland, Ohio",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01523496"
    },
    {
      "nct_id": "NCT03255096",
      "title": "A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma",
        "High-Grade B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "RO6870810",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2017-08-28",
      "completion_date": "2019-07-03",
      "has_results": false,
      "last_update_posted_date": "2022-01-24",
      "last_synced_at": "2026-10-18T00:03:55.226Z",
      "location_count": 4,
      "location_summary": "Duarte, California • Stanford, California • New York, New York + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03255096"
    },
    {
      "nct_id": "NCT05292976",
      "title": "Pharmacodynamic Bioequivalence Study of Albuterol Sulfate Inhalation Aerosol, 0.09 mg Albuterol Base/ Inhalation",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bronchial Asthma"
      ],
      "interventions": [
        {
          "name": "Methacholine Chloride",
          "type": "OTHER"
        },
        {
          "name": "Albuterol Sulfate HFA 0.09 mg (Reference)",
          "type": "DRUG"
        },
        {
          "name": "Albuterol Sulfate HFA 0.18 mg (Reference)",
          "type": "DRUG"
        },
        {
          "name": "Albuterol Sulfate HFA 0.09 mg (Test)",
          "type": "DRUG"
        },
        {
          "name": "Albuterol Sulfate HFA 0.18 mg (Test)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Aurobindo Pharma Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-04",
      "completion_date": "2022-12",
      "has_results": false,
      "last_update_posted_date": "2022-05-20",
      "last_synced_at": "2026-10-18T00:03:55.226Z",
      "location_count": 1,
      "location_summary": "San Jose, California",
      "locations": [
        {
          "city": "San Jose",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05292976"
    },
    {
      "nct_id": "NCT03653676",
      "title": "Sickle Cell Pro-Inflammatory Response to Interval Training Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Exercise Test (CIIT)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "10 Years to 21 Years"
      },
      "enrollment_count": 110,
      "start_date": "2018-01-02",
      "completion_date": "2023-03-17",
      "has_results": false,
      "last_update_posted_date": "2024-12-18",
      "last_synced_at": "2026-10-18T00:03:55.226Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Memphis, Tennessee",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03653676"
    },
    {
      "nct_id": "NCT00001476",
      "title": "Gene Therapy for Chronic Granulomatous Diseases - Long-term Follow-up",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Granulomatous Disease",
        "Communicable Disease"
      ],
      "interventions": [
        {
          "name": "Gene Therapy Method for CGD",
          "type": "DRUG"
        },
        {
          "name": "Isolex 300i Magnetic Cell Selector",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "1995-06-01",
      "completion_date": "2010-12-13",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-18T00:03:55.226Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001476"
    },
    {
      "nct_id": "NCT00183976",
      "title": "Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma",
        "Burkitt Lymphoma",
        "Primary Effusion Lymphomas"
      ],
      "interventions": [
        {
          "name": "Pegylated Liposomal Doxorubicin (Doxil) and Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2005-04",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2014-05-22",
      "last_synced_at": "2026-10-18T00:03:55.226Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00183976"
    },
    {
      "nct_id": "NCT00064389",
      "title": "Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "levalbuterol tartrate HFA MDI",
          "type": "DRUG"
        },
        {
          "name": "racemic albuterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 746,
      "start_date": "2003-01",
      "completion_date": "2005-07",
      "has_results": false,
      "last_update_posted_date": "2012-02-22",
      "last_synced_at": "2026-10-18T00:03:55.226Z",
      "location_count": 91,
      "location_summary": "Birmington, Alabama • Mobile, Alabama • Montgomery, Alabama + 79 more",
      "locations": [
        {
          "city": "Birmington",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Oxford",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00064389"
    }
  ]
}